Proteros announced that it signed a research cooperation agreement with Bayer aimed at identifying new agents for the treatment of cardiovascular diseases. Under the agreement, Proteros will be carrying out the research on a regulating membrane protein over a period of two years in order to achieve defined milestones, while Bayer will be responsible for the optimisation of pre-clinical candidates and clinical development. Proteros will receive payments for its R&D activities as well as milestone payments and royalties from the sale of potential commercial products.